establishment of such a system for SLDs entering developing country markets. Richardson remarked that although serialization of individual units may not be feasible in the short term, the option of printing established G10 numbers (containing either manufacturing or expiry date and batch number) could be adopted in the short term.

INNOVATIVE FINANCING7

Flexible Financing

Issues regarding how best to finance procurement of SLDs resonated throughout the workshop. From a practical standpoint, participants discussed expansion of the funding pool and improvement of its predictability and flexibility. Increased predictability of financing and funding could serve to facilitate program implementation and improve market health, while more flexible financing mechanisms could reduce the amount of funding lost to use. Vincent added that shifting the financing burden for FLDs to countries could free up funding from external donors for SLDs.

In addition to the possibility of pooling procurement processes (discussed earlier), participants also explored the possibility of pooling financing. A. Bloom suggested that under a pooled financing system, purchaser countries could withdraw funding from the broader pool at an appropriate time for purposes of making payment, rather than having to access funds far in advance, when needs may be uncertain due to less accurate forecasting. Several participants discussed the potential for a mechanism incorporating WHO data to monitor pooled financing, procurement, pricing, and drug distribution on a global level to ensure that drugs are being used at the appropriate time in the appropriate place. A. Bloom suggested, given that the Global Fund represents 85 percent of the funding in non-BRICS countries, coordinating with the Global Fund to try to obtain data about how it distributes those funds and how funds flow in and out of those countries, with the view to establishing a more pooled source of funds that could be better matched with the countries’ needs.

___________________

7 This section is based on reflections offered by Prashant Yadav, Director, Healthcare Research Initiative, William Davidson Institute, University of Michigan, and comments offered by workshop participants during an open discussion session moderated by Yadav and Barry Bloom, Harvard University Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health, Department of Immunology and Infectious Diseases, Harvard School of Public Health.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement